ARM is the Global Voice of the Cell & Gene Therapy Sector

Representing 475+ members worldwide

Our focus:

• Convening the sector
• Providing data & analysis
• Engaging key stakeholders
• Enabling the development of advanced therapies
• Modernizing healthcare systems
Jimi Olaghere, Sickle Cell Disease Patient

“Being confident that I have the time and the health to properly take care of my children is a really, really good feeling.”

- Required frequent medical care and spent a considerable amount of time in the hospital
- Participated in the Vertex/CRISPR Therapeutics gene editing trial – treated in September 2020
- Outside of basic clinical trial follow-up, Jimi reports he no longer has any sickle cell care ongoing
Transformative therapies for SCD and hemophilia arrive

The science is advancing & the sector is continuing to mature

- Gene therapies for hemophilia A (BioMarin) and hemophilia B (uniQure/CSL Behring) approved/nearing approval
- 2 gene therapies for sickle cell disease poised for US approval in 2023 (bluebird bio and CRISPR Therapeutics/Vertex)

The era of larger patient populations has arrived – are healthcare systems ready?
Scientific Advances

Approvals and Clinical Milestones
### New Therapies Approved

<table>
<thead>
<tr>
<th>Company</th>
<th>Therapy</th>
<th>Geographies</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Legend Biotech &amp; Janssen</strong></td>
<td>Carvykti</td>
<td>US and EU (CAR-T)</td>
</tr>
<tr>
<td><strong>BioMarin Pharmaceutical</strong></td>
<td>Roctavian</td>
<td>EU (Gene Therapy)</td>
</tr>
<tr>
<td><strong>PTC Therapeutics</strong></td>
<td>Upstaza</td>
<td>EU (Gene Therapy)</td>
</tr>
<tr>
<td><strong>UniQure and CSL Behring</strong></td>
<td>Hemgenix</td>
<td>US (Gene Therapy)</td>
</tr>
<tr>
<td><strong>Ferring Pharmaceuticals</strong></td>
<td>Adstiladrin</td>
<td>US (Gene Therapy)</td>
</tr>
<tr>
<td><strong>Atara Biotherapeutics</strong></td>
<td>Ebvallo</td>
<td>EU (Cell Therapy)</td>
</tr>
</tbody>
</table>

### Therapies Approved in New Geographies or New Indications

<table>
<thead>
<tr>
<th>Company</th>
<th>Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bristol-Myers Squibb</strong></td>
<td>Breyanzi (CAR-T)</td>
</tr>
<tr>
<td><strong>Novartis</strong></td>
<td>Kymriah (CAR-T)</td>
</tr>
<tr>
<td><strong>Kite Pharma (Gilead)</strong></td>
<td>Yescarta (CAR-T)</td>
</tr>
<tr>
<td><strong>bluebird bio inc.</strong></td>
<td>Zynteglo (Gene Therapy)</td>
</tr>
<tr>
<td><strong>bluebird bio inc.</strong></td>
<td>Skysona (Gene Therapy)</td>
</tr>
</tbody>
</table>
2023 regulatory outlook: notable ‘firsts' and milestones
Several potential milestones poised for regulatory decision(s) in the US and/or EU

First CRISPR approval
First US approval of an allogeneic T-cell therapy

Potential Milestones

US: At least 5 gene therapy approvals for rare diseases (5x5x5)
First approval of adoptive cell therapy for solid tumor
First approval for Duchenne Muscular Dystrophy
## Anticipated regulatory decisions in 2023

<table>
<thead>
<tr>
<th>United States</th>
<th>Europe</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Afami-cell (Cell Therapy)</strong>&lt;br&gt;Adaptimmune Therapeutics&lt;br&gt;Advanced synovial sarcoma</td>
<td><strong>Lumevoq (Gene Therapy)</strong>&lt;br&gt;GenSight Biologics SA&lt;br&gt;Leber hereditary optic neuropathy (LHON)</td>
</tr>
<tr>
<td><strong>bb1111 (Gene Therapy)</strong>&lt;br&gt;bluebird bio&lt;br&gt;Sickle cell disease</td>
<td><strong>CT-053 (CAR-T Therapy)</strong>&lt;br&gt;CARsgen Therapeutics&lt;br&gt;R/R multiple myeloma</td>
</tr>
<tr>
<td><strong>EtranaDez (Gene Therapy)</strong>&lt;br&gt;uniQure &amp; CSL Behring&lt;br&gt;Hemophilia B</td>
<td><strong>fidanacogene elaparvec (Gene Therapy)</strong>&lt;br&gt;Pfizer (formerly Spark Therapeutics)&lt;br&gt;Hemophilia B</td>
</tr>
<tr>
<td><strong>HPC cord blood (Cell Therapy)</strong>&lt;br&gt;StemCyte&lt;br&gt;Unrelated Donor hematopoietic progenitor cell transplantation</td>
<td><strong>Libmeldy (Gene Therapy)</strong>&lt;br&gt;Orchard Therapeutics&lt;br&gt;Metachromatic leukodystrophy (MLD)</td>
</tr>
<tr>
<td><strong>Roctavian (Gene Therapy)</strong>&lt;br&gt;BioMarin&lt;br&gt;Hemophilia A</td>
<td><strong>Lifileucel (TIL Therapy)</strong>&lt;br&gt;Iovance&lt;br&gt;Metastatic melanoma</td>
</tr>
<tr>
<td><strong>B-VEC (Gene Therapy)</strong>&lt;br&gt;Krystal Bio&lt;br&gt;Dystrophic epidermolysis bullosa</td>
<td><strong>Omidubicel (Cell Therapy)</strong>&lt;br&gt;Gamida Cell&lt;br&gt;Hematological malignancies</td>
</tr>
<tr>
<td><strong>CTX001 (Gene Editing Therapy)</strong>&lt;br&gt;CRISPR Therapeutics &amp; Vertex Pharmaceuticals&lt;br&gt;Duchenne muscular dystrophy</td>
<td><strong>Tab-cel (Cell Therapy)</strong>&lt;br&gt;Atara Biotherapeutics Inc&lt;br&gt;Epstein-Barr virus-associated post-transplant lymphoproliferative disorder (EBV+PTLD)</td>
</tr>
<tr>
<td><strong>B-VEC (Gene Therapy)</strong>&lt;br&gt;Krystal Bio&lt;br&gt;Dystrophic epidermolysis bullosa</td>
<td><strong>Upstaza (Gene Therapy)</strong>&lt;br&gt;PTC Therapeutics&lt;br&gt;Aromatic L-amino acid decarboxylase (AADC) deficiency</td>
</tr>
<tr>
<td><strong>Letterine (Gene Therapy)</strong>&lt;br&gt;uniQure &amp; CSL Behring&lt;br&gt;Hemophilia B</td>
<td><strong>CTX001 (Gene Editing Therapy)</strong>&lt;br&gt;CRISPR Therapeutics &amp; Vertex Pharmaceuticals&lt;br&gt;Sickle cell disease, β-thalassemia</td>
</tr>
<tr>
<td><strong>EtranaDez (Gene Therapy)</strong>&lt;br&gt;uniQure &amp; CSL Behring&lt;br&gt;Hemophilia B</td>
<td><strong>Lumevoq (Gene Therapy)</strong>&lt;br&gt;GenSight Biologics SA&lt;br&gt;Leber hereditary optic neuropathy (LHON)</td>
</tr>
</tbody>
</table>
As we enter 2023...

2,220 clinical trials active
• 43% w/sites in NA; 38% APAC; 18% EUR
• 254 new in 2022 (48% w/sites in APAC)
• 202 trials in phase 3
• More than 100 gene editing trials

58% of trials have potential applications in a prevalent disorder

60% of trials focus on oncology
• Near equal representation of solid & liquid tumors
Cell and Gene Therapy Investment
Continued resilience in the face of significant macro headwinds
1,457
Cell and gene therapy developers worldwide
Up 11% YoY

North America
686

Europe
244

Asia Pacific
492

All Other Regions
35
Market Factors Depress Public Equity Performance

Public Equity 2022

- NASDAQ Global (NQGI)
- S&P 500 (GSPC)
- NASDAQ Biotech (NBI)
- S&P Biotech (XBI)
- RMAT Index (ARM)
- Gene Therapy Index (ARM)
- CB 10 Index (ARM)
Investments “return to normal”

$12.6B raised in 2022

$7.5B  $13.3B  $9.8B  $19.9B  $22.7B  $12.6B

2017  2018  2019  2020  2021  2022

1. Includes upfront payments; excludes milestones, M&A, academic or government grants
Modernizing Healthcare to Ensure Patient Access

An opportunity we can't miss
2023+: The biggest test yet?

The science behind cell and gene therapies is progressing rapidly – to the immense benefit of patients

A highly dynamic time for healthcare systems – including payors and regulators

• Larger patient populations than with previous therapies
• Will new therapies be a “forcing function” for payers to adapt?
• Can they modernize to keep pace with the science?
US: The CGT wave arrives, to the benefit of patients

Up to 14 regulatory decisions expected

The FDA is evolving, by design, in order to keep pace
• Reorganization of OTAT to OTP ‘super office’
• Filling current vacancies
• PDUFA VII adding 100 new reviewers in next five years
• CMC: PDUFA readiness pilot & potency assay workshop

Questions linger about US payor readiness
• We need to modernize payment systems across Medicaid, Medicare and private insurers and expedite access to CGTs
EU: Urgent action needed to ensure patient access

Once a leader, the EU is now ‘a flashing yellow light of caution’ for patient access:

• Roadblocks in reimbursement have complicated patient access
• 7 of the 24 approved ATMPs have been pulled from the market
• Clinical trials and investment stagnating – only 3 new Phase 1 trials in 2022

However, a fork in the road exists with near term choices that will impact patients...
EU: Opportunity to choose a better path for patients
Once in a generation chance to reverse this trend

Revising the EU Pharmaceuticals Legislation
• Avoid one-size-fits-all approach – based on “pills of the past”
• Exempt ATMP clinical trials from GMO legislation
• Hospital exemption: Only for high unmet need and when there are no treatment alternatives

EU Health Technology Assessment
• Provide clear EU-wide guidelines for the use of real-world evidence (RWE); alternative to randomized clinical trials
• Leverage Health Data Space to collect RWE
• Continued collaboration with developers throughout Joint Clinical Assessment process
What will 2023 tell us about the future of CGTs?

Are healthcare systems modernizing...or clinging to the past?

How willing are patients to embrace new technologies?

• What will this signal for emerging therapies for prevalent diseases?

What are the implications for patients, developers, and investors?

2023 will send important signals...but where will we be in 2028?
Patient spotlight: Lucy Ellerker

“We think CAR-T should be the first line of treatment, not the last.” – Lucy Ellerker, Parent of CAR-T recipient

Patients are waiting for life-changing, life-saving treatments

We have an opportunity to build the future of medicine, together
In closing...

After walking for many years, CGTs began to jog in 2022

CGTs are poised to begin to run in 2023... but significant hurdles exist

Real running is attainable – but only if we modernize our approach to healthcare in the US and across the EU
Thank you.